PDS Biotechnology Corporation (PDSB) shares took a nosedive on Tuesday, dropping about 67%, after the company announced a major strategic shift. The biotech firm is now prioritizing its PDS0301 program, which targets metastatic colorectal cancer, over other pipeline candidates.
PDS Biotechnology Stock Crashes as Company Pivots to Colorectal Cancer Program
MarketDash
PDS Biotechnology shares plummet after the company announces a strategic refocus on its PDS0301 metastatic colorectal cancer program.
Get PDS Biotechnology Alerts
Weekly insights + SMS alerts
PDS0301 Metastatic Colorectal Cancer Focus
The decision to focus on PDS0301 is part of a broader refocusing effort, reflecting the company's commitment to advancing its immunotherapy pipeline built on its proprietary Versamune platform technology. In a statement, the company explained the rationale: "We concluded that our resources should be redirected toward PDS0301, where we believe the combination of encouraging clinical data, development opportunity and capital requirements provide a potentially more attractive path to long-term shareholder value."
CEO Frank Bedu-Addo also addressed shareholders in a letter, saying, "We believe the strength of the Phase 2 clinical results allows us to preserve the potential value of PDS0101 through a strategic partnership." This suggests that while PDS0101 is being deprioritized, the company sees enough promise in it to seek a partner rather than abandon it entirely.
PDSB Technical Outlook: Oversold Conditions And Downtrend
From a technical standpoint, PDS Biotechnology's stock is in rough shape. The current price sits at 24 cents, which is about 62.5% below the 20-day simple moving average (SMA) of 69 cents. The Relative Strength Index (RSI) is at 17.90, putting the stock firmly in oversold territory. That might sound like a potential rebound is in the cards, but the broader trend tells a different story.
The 50-day SMA is at 84 cents, meaning the stock is trading 69.1% below that level. Adding to the bearish picture, a death cross occurred in August when the 50-day SMA crossed below the 200-day SMA, a classic signal that the downtrend could continue.
PDSB Price Action: At the time of publication on Tuesday, PDS Biotechnology shares were down 64.01% to $0.26, hitting a new 52-week low, according to market data.
For investors, the key takeaway is that PDS Biotechnology is making a calculated bet on PDS0301, but the market's reaction suggests skepticism about the near-term prospects. The oversold conditions might attract bargain hunters, but the technical indicators warn that the stock could face further pressure before any meaningful recovery.
More News
Inflation Cools to 3.4% as Expected in July: Is This Enough for the Fed? (UPDATED)
Get a Stake in OpenAI and Anthropic — Today
AI Earnings and a Benign CPI Give Stocks a Midweek Boost
CoreWeave Stock Surges on AI Price Hikes and Raised Guidance
Nokia Stock Jumps 10% as AI Data Center Demand Fuels a Beat-and-Raise Story
Trump's Secret Retirement Fund
Intel's $20 Billion Raise: A Bold Bet on Foundry, Not a Bailout
Nebius Says AI Demand Is So Hot It Could Sell Out 2027 Today
Get PDS Biotechnology Alerts
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
Featured Articles
View all newsInflation Cools to 3.4% as Expected in July: Is This Enough for the Fed? (UPDATED)
By MarketDash
August 12, 2026
Trump and Elon Are Back (Ad)
By Stansberry Research
AI Earnings and a Benign CPI Give Stocks a Midweek Boost
By MarketDash
August 12, 2026
CoreWeave Stock Surges on AI Price Hikes and Raised Guidance
By MarketDash
August 12, 2026
Nokia Stock Jumps 10% as AI Data Center Demand Fuels a Beat-and-Raise Story
By MarketDash
August 12, 2026
Elon “xPhone” Exposed (Ad)
By Timothy Sykes
Intel's $20 Billion Raise: A Bold Bet on Foundry, Not a Bailout
By MarketDash
August 12, 2026
Nebius Says AI Demand Is So Hot It Could Sell Out 2027 Today
By MarketDash
August 12, 2026